首页> 外文期刊>Expert review of anti-infective therapy >Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials
【24h】

Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials

机译:基于以前试验的不同类型的急性呼吸道感染的ProCalcitonin引导抗生素治疗算法

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Although evidence indicates that use of procalcitonin to guide antibiotic decisions for the treatment of acute respiratory infections (ARI) decreases antibiotic consumption and improves clinical outcomes, algorithms used within studies had differences in PCT cut-off points and frequency of testing. We therefore analyzed studies evaluating procalcitonin-guided antibiotic therapy and propose consensus algorithms for different respiratory infection types. Areas covered: We systematically searched randomized-controlled trials (search strategy updated on February 2018) on procalcitonin-guided antibiotic therapy of ARI in adults using a pre-specified Cochrane protocol and analyzed algorithms from 32 trials that included 10,285 patients treated in primary care settings, emergency departments (ED), and intensive care units (ICU), We derived consensus algorithms for use of procalcitonin by the type of ARI including community-acquired pneumonia, bronchitis, chronic obstructive pulmonary disease or asthma exacerbation, sepsis, and postoperative sepsis due to respiratory infection. Consensus algorithm recommendations differ with regard to timing of treatment (i.e. timing of initiation in low-risk patients or discontinuation in high-risk patients) and procalcitonin cut-off points for the recommendation/strong recommendation to discontinue antibiotics (≤ 0.25/≤ 0.1 μg/L in ED and inpatients, ≤ 0.5/≤ 0.25 μg/L in ICU patients, and reduction by ≥ 80% from peak levels in sepsis patients). Expert commentary: Our proposed algorithms may facilitate safe and efficient implementation of procalcitonin-guided antibiotic protocols in diverse healthcare settings. Still, the decision about initiation and cessation of antibiotic treatment remains a clinical decision based on the patient assessment and the severity of illness and use of procalcitonin should not delay empirical treatment in high risk situations.
机译:介绍:虽然证据表明,使用ProCalcitonin指导治疗急性呼吸道感染的抗生素决定降低抗生素消耗并提高临床结果,研究中使用的算法在PCT截止点和测试频率下具有差异。因此,我们分析了评估ProCalciton引导抗生素治疗的研究,并提出了不同呼吸道感染类型的共识算法。所涵盖的地区:我们系统地搜索了使用预先指定的Cochrane方案的成人在成人的ProCalcitonin引导抗生素治疗和分析了来自初级保健环境中的32例患者的32例试验中的血管基因因子抗生素治疗,紧急部门(ED)和重症监护单位(ICU),我们通过ARI的类型衍生出用于使用ProCalcitonin的共识算法,包括社区获得的肺炎,支气管炎,慢性阻塞性肺病或哮喘加剧,败血症和术后术后脓毒症呼吸道感染。共识算法建议在治疗时间方面不同(即,低风险患者的开始时间或在高危患者中停药)和ProCalcitonin截止点,用于停止抗生素的建议/强大建议(≤0.25/≤0.1μg ICU患者的ED和住院患者,≤0.5/≤0.25μg/ L,败血症患者的峰值水平降低≥80%)。专家评论:我们所提出的算法可以促进在不同的医疗保健环境中安全有效地实施ProCalcitonIn引导抗生素方案。尽管如此,关于抗生素治疗的启动和停止的决定仍然是基于患者评估的临床决策,并且疾病的严重程度和ProCalcitonin的使用不应延迟高风险情况的实证治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号